Key facts
- It has raised $89.0M; the latest was Early Stage VC ($50.0M) in Dec 2025.
- Notable investors include Legend Capital, 5Y Capital, Lanchi Ventures, YuanBio Venture Capital, Lapam Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Allink Biotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Allink Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Allink Biotherapeutics
Developer of oncology drugs intended to discover and advance antibody-based therapeutics for oncology and immunology. The company offers integrated platforms for bispecific antibody engineering, conjugation chemistry for antibody-drug constructs, preclinical data assembly, and clinical-stage program management informed by biomarker strategies, enabling biopharma teams, clinical researchers, and translational scientists to evaluate targets rigorously, structure trials more efficiently, and progress candidates with traceable methods and documented performance across multiple disease areas.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2023
- Website
- allinkbio.com/
- Ownership
- Privately Held (backing)
Allink Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allink Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allink Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.